All News

Tisagenlecleucel (Kymriah) is a personalized genetically-modified autologous T cell immunotherapy designed to use a patient’s own T cells to target and kill leukemia.

Officials with the FDA have issued a historic approval of the first Chimeric Antigen Receptor (CAR) T-Cell Therapy to be available in the United States.

Tisagenlecleucel is indicated for pediatric and young adult patients with B-cell precursor acute lymphoblastic leukemia.

Statins may provide a protective effect against breast cancer development.

Amyloid plaques accumulate in the retinas of patients with Alzheimer’s disease.

Approximately 12,000 customers were affected by the breach.

In MAPS' completed phase 2 trials with 107 participants, 61% no longer qualified for PTSD after 3 sessions of MDMA-assisted psychotherapy 2 months following treatment.

Epigenetic drugs may reduce viral reactivation of herpes and other viruses.

Scientists hone in on personalized treatments for patients with cancer.

Increasing sleep by a half hour significantly reduced body weight and insulin resistance.

Study examines how a school nursing intervention helped reduce missed school days.

Top news of the day from across the health care landscape.

An estimated 1.2 million American women would likely benefit from recommended genetic test to assess their risk of cancer.

Top news of the day from across the healthcare landscape.

A recently-published study evaluated increasing concerns that plaque psoriasis medications may trigger inflammatory bowel disease (IBD).

The risk of developing liver cancer is similar with direct-acting antiviral drugs or interferon therapy for hepatitis C virus.

Benznidazole granted accelerated approval for use in children aged 2 to 12 years with Chagas disease.

It is the first treatment approved in the United States for the treatment of Chagas disease.

Officials with the FDA have announced the approval of Vabomere (Rempex) for the treatment of complicated urinary tract infections (cUTI).

Attendees of the National Association of Specialty Pharmacy annual meeting have the chance to see the nation’s capital during downtime.

A lawsuit that alleged CVS conspired with PBMs to increase costs was dropped on the grounds of incorrect information presented in the case.

Boehringer said they also plan to seek approval for an auto-injector of the biosimilar to expand options for patients.

Cyltezo is the first biosimilar developed by Boehringer Ingelheim to be approved by the FDA.

Cyltezo approved for the same indications as Humira, including rheumatoid arthritis, psoriatic arthritis, and Crohn’s disease.

The $2 million grant seeks to help establish guidelines for further development of treatments for HIV.

Abnormal eating times shown to increase susceptibility to daytime ultraviolet rays.

Alcohol consumption results in more than $150 million spent on breast cancer annually.

A selective assessment method may lead to earlier diagnosis and treatment of Alzheimer’s disease.

Top news of the day from across the healthcare landscape.

Top news of the day from across the healthcare landscape.